Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Sionna Therapeutics (SION) has drawn attention after ...

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...

Live webcasts of the presentations can be accessed in the 'Investors' section of Sionna's website at . Replays will also be available following the events. Sionna Therapeutics is a clinical-stage ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic fibrosis (CF), which offer a different mechanism to those sold by market ...

Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated ...

(MENAFN- GlobeNewsWire - Nasdaq) Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on ...

In other recent news, Sionna Therapeutics has been the focus of several analyst reports. Citizens initiated coverage on Sionna Therapeutics with a Market Outperform rating and set a price target of ...

Fintel reports that on February 24, 2026, Citizens initiated coverage of Sionna Therapeutics (NasdaqGM:SION) with a Market Outperform recommendation. Analyst Price Forecast Suggests 26.74% Upside As ...

Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs) on the Nasdaq, taking the number in the newly-filed queue to four since the start of the year. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.